[go: up one dir, main page]

NZ292980A - Smooth, spherical water-soluble microparticles as therapeutic or diagnostic vehicles - Google Patents

Smooth, spherical water-soluble microparticles as therapeutic or diagnostic vehicles

Info

Publication number
NZ292980A
NZ292980A NZ292980A NZ29298095A NZ292980A NZ 292980 A NZ292980 A NZ 292980A NZ 292980 A NZ292980 A NZ 292980A NZ 29298095 A NZ29298095 A NZ 29298095A NZ 292980 A NZ292980 A NZ 292980A
Authority
NZ
New Zealand
Prior art keywords
therapeutic
smooth
spherical water
soluble microparticles
diagnostic
Prior art date
Application number
NZ292980A
Inventor
Andrew Derek Sutton
Richard Alan Johnson
Original Assignee
Andaris Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andaris Ltd filed Critical Andaris Ltd
Publication of NZ292980A publication Critical patent/NZ292980A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Radiology & Medical Imaging (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ292980A 1994-09-29 1995-09-26 Smooth, spherical water-soluble microparticles as therapeutic or diagnostic vehicles NZ292980A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94307126 1994-09-29
PCT/GB1995/002279 WO1996009814A1 (en) 1994-09-29 1995-09-26 Spray-dried microparticles as therapeutic vehicles

Publications (1)

Publication Number Publication Date
NZ292980A true NZ292980A (en) 1999-02-25

Family

ID=8217866

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ292980A NZ292980A (en) 1994-09-29 1995-09-26 Smooth, spherical water-soluble microparticles as therapeutic or diagnostic vehicles

Country Status (16)

Country Link
EP (1) EP0783298A1 (en)
JP (1) JPH10506406A (en)
KR (1) KR970705979A (en)
AU (1) AU701440B2 (en)
BR (1) BR9509171A (en)
CA (1) CA2199954A1 (en)
CZ (1) CZ92497A3 (en)
FI (1) FI971332L (en)
HU (1) HUT77373A (en)
MX (1) MX9702357A (en)
NO (1) NO971438L (en)
NZ (1) NZ292980A (en)
PL (1) PL319600A1 (en)
RU (1) RU2147226C1 (en)
WO (1) WO1996009814A1 (en)
ZA (1) ZA958239B (en)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
CZ295827B6 (en) 1994-03-07 2005-11-16 Nektar Therapeutics Method for aerosolizing a dose of insulin, insulin composition and use thereof
US5955108A (en) * 1994-12-16 1999-09-21 Quadrant Healthcare (Uk) Limited Cross-linked microparticles and their use as therapeutic vehicles
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
GB9606677D0 (en) * 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
GB9607035D0 (en) * 1996-04-03 1996-06-05 Andaris Ltd Spray-dried microparticles as therapeutic vehicles
WO1997044015A1 (en) * 1996-05-17 1997-11-27 Andaris Limited Microparticles and their use in wound therapy
GB9610341D0 (en) * 1996-05-17 1996-07-24 Andaris Ltd Formulation for inhalation
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US20020052310A1 (en) 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
GB9615435D0 (en) 1996-07-23 1996-09-04 Andaris Ltd Spray-dried product and its therapeutic use
WO1998017318A1 (en) * 1996-10-19 1998-04-30 Quadrant Healthcare (Uk) Limited Use of hollow microcapsules in diagnosis and therapy
GB9621825D0 (en) * 1996-10-19 1996-12-11 Andaris Ltd Microparticles and their use as therapeutic vehicles
US5976574A (en) * 1996-12-31 1999-11-02 Inhale Therapeutic Systems Processes for spray drying hydrophobic drugs in organic solvent suspensions
WO1998031346A1 (en) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
EP1498115A1 (en) * 1997-01-16 2005-01-19 Massachusetts Institute Of Technology Preparation of particles for inhalation
SE9700133D0 (en) * 1997-01-20 1997-01-20 Astra Ab New formulation
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
IL135126A0 (en) * 1997-09-29 2001-05-20 Inhale Therapeutic Syst Perforated microparticles and methods of use and preparation thereof
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
SE9704186D0 (en) 1997-11-14 1997-11-14 Astra Ab New composition of matter
GB9727102D0 (en) * 1997-12-22 1998-02-25 Andaris Ltd Microparticles and their therapeutic use
EP1056484A1 (en) * 1998-02-20 2000-12-06 Quadrant Healthcare (UK) Limited Products comprising fibrinogen for use in therapy
ATE238768T1 (en) * 1998-06-24 2003-05-15 Advanced Inhalation Res Inc LARGE POROUS PARTICLES EXPECTED FROM AN INHALER
EP1273290A1 (en) * 1998-06-24 2003-01-08 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
EP1169065B1 (en) * 1999-04-21 2005-03-02 1355540 Ontario Inc. Methacoline or histamine formulations for detecting asthma
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
AU778931B2 (en) 1999-12-20 2004-12-23 Nicholas J. Kerkhof Process for producing nanometer particles by fluid bed spray-drying
US8771740B2 (en) * 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
TWI290473B (en) 2000-05-10 2007-12-01 Alliance Pharma Phospholipid-based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
AU2001264789A1 (en) * 2000-06-08 2001-12-17 Eli Lilly And Company Protein powder for pulmonary delivery
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
AU2002241723A1 (en) * 2000-12-21 2002-07-24 Inhale Therapeutic Systems, Inc. Storage stable powder compositions of interleukin-4 receptor
CA2433335C (en) 2000-12-29 2010-04-20 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
GB0111420D0 (en) * 2001-05-10 2001-07-04 Biovector Solutions Ltd Soluble polymer systems for drug delivery
KR100951750B1 (en) 2001-11-01 2010-04-09 노바르티스 아게 Spray drying method and composition
AU2002352836B2 (en) 2001-11-20 2005-09-29 Alkermes, Inc. Improved particulate compositions for pulmonary delivery
ES2364636T3 (en) 2001-12-19 2011-09-08 Novartis Ag PULMONARY ADMINISTRATION OF AMINOGLUCOSIDS.
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
AU2003299795A1 (en) 2002-12-20 2004-07-22 Xeris Pharmaceuticals, Inc. Intracutaneous injection
JP2007500234A (en) 2003-05-28 2007-01-11 ネクター セラピューティクス Pharmaceutical moldings containing active agents insoluble in water
KR101137785B1 (en) 2003-07-18 2012-04-25 백스터 인터내셔널 인코포레이티드 Methods for Fabrication, Uses and Compositions of Small Spherical Particles Prepared by Controlled Phase Separation
DE10339197A1 (en) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried amorphous powder with low residual moisture and good storage stability
US7723306B2 (en) 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
WO2005112893A1 (en) 2004-05-12 2005-12-01 Baxter International Inc. Microspheres comprising protein and showing injectability at high concentrations of said agent
US9017697B2 (en) 2006-10-12 2015-04-28 The University Of Queensland Compositions and methods for modulating immune responses
EP2050437A1 (en) * 2007-10-15 2009-04-22 Laboratoires SMB Improved pharmaceutical dry powder compositions for inhalation.
UA90013C2 (en) * 2008-03-19 2010-03-25 Давид Анатолійович Нога Pharmaceutical composition containing insulin and process for the preparation thereof
US10463608B2 (en) 2008-09-29 2019-11-05 The Corporation Of Mercer University Microneedle-based transdermal delivery system and method of making same
WO2010037142A1 (en) 2008-09-29 2010-04-01 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
US11524058B2 (en) 2008-09-29 2022-12-13 The Corporation Of Mercer University Oral dissolving films containing microencapsulated vaccines and methods of making same
US10004790B2 (en) 2008-09-29 2018-06-26 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
US9827205B2 (en) 2008-12-12 2017-11-28 Mallinckrodt Pharma Ip Trading D.A.C. Dry powder fibrin sealant
EP2216054A1 (en) 2009-02-06 2010-08-11 ProFibrix BV Biodegradable extravascular support
GB0909136D0 (en) 2009-05-28 2009-07-01 Profibrix Bv Dry powder composition
AU2010252929B2 (en) * 2009-05-28 2015-08-27 Mallinckrodt Pharma Ip Trading D.A.C. Dry powder fibrin sealant
GB0909131D0 (en) 2009-05-28 2009-07-01 Quadrant Drug Delivery Ltd Dry powder fibrin sealant
WO2011005756A1 (en) 2009-07-06 2011-01-13 Puretech Ventures, Llc Delivery of agents targeted to microbiota niches
NZ600812A (en) 2010-01-08 2014-08-29 Profibrix Bv Dry powder fibrin sealant
US20120046225A1 (en) 2010-07-19 2012-02-23 The Regents Of The University Of Colorado, A Body Corporate Stable glucagon formulations for the treatment of hypoglycemia
JP2013545453A (en) 2010-11-01 2013-12-26 ユニバーシティ・オブ・テクノロジー、シドニー Immunomodulators and their use
BR112013023062B1 (en) 2011-03-10 2022-01-18 Xeris Pharmaceuticals, Inc STABLE SOLUTION FOR PARENTERAL INJECTION AND MANUFACTURING METHOD OF IT
EP3225235B1 (en) 2011-03-10 2020-12-16 Xeris Pharmaceuticals, Inc. Stable peptide formulations for parenteral injection
RU2013155713A (en) 2011-07-06 2015-08-20 Профибрикс Бв COMPOSITIONS FOR TREATMENT OF THE RAS
JP6117811B2 (en) 2011-10-31 2017-04-19 ゼリス ファーマシューティカルズ インコーポレイテッド Formulations for treating diabetes
CN104470503A (en) 2012-04-13 2015-03-25 葛兰素史克知识产权开发有限公司 Aggregate particles
JP6420761B2 (en) * 2012-06-26 2018-11-07 ジーイー・ヘルスケア・アクスイェ・セルスカプ Preparation of compositions containing gaseous microbubbles
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
WO2014121137A2 (en) 2013-02-01 2014-08-07 Glialogix, Inc. Compositions and methods for the treatment of neurodegenerative and other diseases
WO2014124096A1 (en) 2013-02-06 2014-08-14 Perosphere Inc. Stable glucagon formulations
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
JP6529012B2 (en) 2013-10-08 2019-06-12 エイアイ・セラピューティクス・インコーポレーテッド Rapamycin for the treatment of lymphangiyomyomatosis
NZ724756A (en) 2014-04-04 2023-07-28 Ai Therapeutics Inc An inhalable rapamycin formulation for treating age-related conditions
ES2936067T3 (en) 2014-05-27 2023-03-14 Univ Queensland IL-22 for use in the treatment of metabolic disorders
AU2015300944B2 (en) 2014-08-06 2019-07-11 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
BR112017006842A2 (en) 2014-10-07 2017-12-12 Lam Therapeutics Inc Inhalable rapamycin formulation for the treatment of pulmonary hypertension
WO2016196976A1 (en) 2015-06-04 2016-12-08 Xeris Pharmaceuticals, Inc. Glucagon delivery apparatuses and related methods
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
EP3307295A1 (en) 2015-06-10 2018-04-18 Xeris Pharmaceuticals, Inc. Use of low dose glucagon
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
US11628208B2 (en) 2015-10-05 2023-04-18 The Corporation Of Mercer University System and method for microneedle delivery of microencapsulated vaccine and bioactive proteins
WO2017062463A1 (en) 2015-10-05 2017-04-13 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
WO2018075865A1 (en) 2016-10-21 2018-04-26 Glialogix, Inc. Compositions for the treatment of neurodegenerative diseases
WO2018222922A1 (en) 2017-06-02 2018-12-06 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
WO2021090214A2 (en) * 2019-11-04 2021-05-14 Alesco S.R.L. Sucrosomial® berberine, its compositions and their use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2159524T3 (en) * 1992-06-12 2001-10-16 Teijin Ltd PHARMACEUTICAL PREPARATION TO BE ADMINISTERED INSIDE THE RESPIRATORY ROADS.
DE69332240T2 (en) * 1992-06-12 2003-04-10 Teijin Ltd., Osaka ULTRA FINE POWDER FOR INHALATION AND PRODUCTION

Also Published As

Publication number Publication date
ZA958239B (en) 1996-09-30
NO971438D0 (en) 1997-03-26
HUT77373A (en) 1998-03-30
KR970705979A (en) 1997-11-03
AU701440B2 (en) 1999-01-28
FI971332A0 (en) 1997-04-01
CZ92497A3 (en) 1997-08-13
CA2199954A1 (en) 1996-04-04
JPH10506406A (en) 1998-06-23
BR9509171A (en) 1997-09-16
WO1996009814A1 (en) 1996-04-04
EP0783298A1 (en) 1997-07-16
FI971332L (en) 1997-04-01
NO971438L (en) 1997-03-26
RU2147226C1 (en) 2000-04-10
AU3530295A (en) 1996-04-19
MX9702357A (en) 1997-06-28
PL319600A1 (en) 1997-08-18

Similar Documents

Publication Publication Date Title
NZ292980A (en) Smooth, spherical water-soluble microparticles as therapeutic or diagnostic vehicles
EP0668052A3 (en) Ultrasonic diagnosis and treatment system.
AU2277501A (en) One-step system for cleansing, conditioning, and treating the skin
EP0690023A3 (en) Xerogels, process for their preparation and their use
EP0710667A3 (en) Modified oligonucleotides, their preparation and their use
ZA9711029B (en) Therapeutic agents.
IL150022A0 (en) Imidazo [1,3,5] triazinones and the use thereof
HRP970450B1 (en) Phenyl-substituted alkenoylguanidides, process for their preparation, their use as drugs or diagnostic agents and drugs containing them
GB9811738D0 (en) Tyre diagnostic system
HUP9904104A3 (en) Derivates from piperidine-keto acid,their preparation and use
GB9607035D0 (en) Spray-dried microparticles as therapeutic vehicles
HK1001286A1 (en) Benzopyrans and their use as therapeutic agents.
EP0671631A3 (en) Vehicle diagnostic apparatus.
HUP9904206A3 (en) 1,4-diazabicyclo[2.2.2.]oct-2-ylmethyl derivatives,their preparation and therapeutic application
ZA979372B (en) Porous microcapsules and their use as therapeutic and diagnostic vehicles
AU2208097A (en) Muscular dystrophy, stroke, and neurodegenerative disease diagnosis and treatment
ZA976479B (en) Alfa-amino acids amides, preparation thereof and the therapeutical use thereof.
ZA965494B (en) Therapeutic agents.
EP0855982A4 (en) Car body part
HRP970424B1 (en) Substituted indanylidineacetylguanidines, process for their preparation, their use as medicaments or diagnostic agents and medicaments containing them
ZA985291B (en) Air treatment system.
GB9700322D0 (en) Shampoo and conditioner for hair and/or for the body
GB9704876D0 (en) Diagnostic methods
IL114235A0 (en) Oligonucleotide conjugates and processes for noninvasive diagnosis utilizing the same
AU4112097A (en) Bismuth dendrimers, processes for their preparation, and their use as x-ray contrast agents

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: QUADRANT HOLDINGS CAMBRIDGE LIMITED, GB

Free format text: OLD OWNER(S): QUADRANT HEALTHCARE (UK) LIMITED

ASS Change of ownership

Owner name: QUADRANT DRUG DELIVERY LIMITED, GB

Free format text: OLD OWNER(S): QUADRANT DRUG DELIVERY LIMITED; QUADRANT HEALTHCARE (UK) LIMITED

Owner name: QUADRANT DRUG DELIVERY LIMITED, GB

Free format text: OLD OWNER(S): QUADRANT DRUG DELIVERY LIMITED; QUADRANT HOLDINGS CAMBRIDGE LIMITED

RENW Renewal (renewal fees accepted)
EXPY Patent expired